---
title: "Enliven Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285611677.md"
datetime: "2026-05-07T20:25:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285611677.md)
  - [en](https://longbridge.com/en/news/285611677.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285611677.md)
---

# Enliven Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.38, beating the estimate of USD -0.465.

#### Cash Position

Enliven Therapeutics, Inc. reported cash, cash equivalents, and marketable securities of $452.4 million as of March 31, 2026, a decrease from $462.6 million as of December 31, 2025. This cash position is projected to provide a cash runway into the first half of 2029.

#### Research and Development (R&D) Expenses

R&D expenses for the first quarter of 2026 were $20.7 million, down from $24.9 million for the first quarter of 2025.

#### General and Administrative (G&A) Expenses

G&A expenses for the first quarter of 2026 were $7.1 million, an increase from $6.8 million for the first quarter of 2025.

#### Total Operating Expenses

Total operating expenses for the first quarter of 2026 were $27.823 million, a decrease from $31.693 million for the first quarter of 2025.

#### Loss from Operations

Enliven Therapeutics, Inc. reported a loss from operations of - $27.823 million for the first quarter of 2026, an improvement from - $31.693 million for the first quarter of 2025.

#### Other Income (Expense), Net

Other income (expense), net, was $4.196 million for the first quarter of 2026, compared to $3.149 million for the first quarter of 2025.

#### Net Loss

The company reported a net loss of - $23.6 million for the first quarter of 2026, an improvement from a net loss of - $28.5 million for the first quarter of 2025.

#### Net Loss Per Share

Net loss per share, basic and diluted, was - $0.38 for the first quarter of 2026, compared to - $0.57 for the first quarter of 2025.

#### Weighted-Average Shares Outstanding

Weighted-average shares outstanding, basic and diluted, were 62.799 million for the first quarter of 2026, an increase from 50.051 million for the first quarter of 2025.

#### Operational Highlights

In January 2026, Enliven Therapeutics, Inc. announced positive initial Phase 1b data for ELVN-001, reinforcing its potential as a best-in-class ATP-competitive inhibitor in Chronic Myeloid Leukemia (CML). Enrollment has continued in the 80 mg once daily expansion cohort of the Phase 1b trial evaluating ELVN-001 in previously treated CML patients.

#### Outlook and Guidance

Enliven Therapeutics, Inc. anticipates presenting additional Phase 1 data from the ENABLE trial mid-year 2026 and engaging in regulatory interactions with the FDA regarding dose selection and Phase 3 trial design. The company expects to initiate the Phase 3 ENABLE-2 pivotal trial of ELVN-001 in the second half of 2026. Its current cash, cash equivalents, and marketable securities are expected to fund operations into the first half of 2029.

### Related Stocks

- [ELVN.US](https://longbridge.com/en/quote/ELVN.US.md)

## Related News & Research

- [Enliven Therapeutics (NASDAQ:ELVN) Director Sells 1,230 Shares](https://longbridge.com/en/news/273435509.md)
- [16:05 ETEnliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update](https://longbridge.com/en/news/285607145.md)
- [Enliven Therapeutics (ELVN) Projected to Post Earnings on Wednesday](https://longbridge.com/en/news/285371284.md)
- [LifeSci Capital Keeps Their Buy Rating on Enliven Therapeutics (ELVN)](https://longbridge.com/en/news/280882703.md)
- [Enliven Therapeutics Q4 net loss widens on higher expenses](https://longbridge.com/en/news/277680010.md)